| Description |
1 online resource (xxiii, 754 pages) : illustrations |
| Contents |
""Book Cover""; ""Half-Title""; ""Title""; ""Copyright""; ""Contents""; ""Contributors""; ""Preface to First Edition""; ""Preface to Second Edition""; ""Acknowledgements""; ""I Introduction""; ""1 Aspects of multiple sclerosis that relate to clinical trial design and treatment ""; ""II Clinical trial methodology""; ""2 Measures of neurologic impairment and disability in multiple sclerosis""; ""3 Assessment of neuropsychological function in multiple sclerosis""; ""4 Health-related quality of life assessment in multiple sclerosis"" |
|
""5 Magnetic resonance imaging in multiple sclerosis: an overview""""6 Measures of gadolinium enhancement in multiple sclerosis ""; ""7 Measures of magnetization transfer in multiple sclerosis""; ""8 Measures of T1 and T2 relaxation in multiple sclerosis""; ""9 Measurement of central nervous system atrophy""; ""10 Measures to quantify axonal damage in vivo based on magnetic resonance spectroscopy in multiple sclerosis""; ""11 Functional imaging in multiple sclerosis""; ""12 Use of cost analyses to improve understanding of the therapeutic trade-offs for multiple sclerosis"" |
|
""13 Ethical considerations in multiple sclerosis clinical trials""""14 The process of drug development and approval in the USA, the European Union, and Canada""; ""15 Sponsors, monitoring committees and investigators: the investigator�s perspective""; ""16 Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials""; ""17 The failed clinical trial in multiple sclerosis"" |
|
""18 The challenge of long-term studies in multiple sclerosis: use of pooled data, historical controls, and observational studies to determine efficacy""""19 Emerging concepts of pathogenesis: relationship to therapies for multiple sclerosis""; ""III Clinical trials of disease-modifying therapy""; ""33 Complementary and alternative treatments in multiple sclerosis""; ""32 Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis""; ""31 Combination therapies in multiple sclerosis""; ""30 Emerging disease-modifying therapies for multiple sclerosis"" |
|
""29 Treatment of multiple sclerosis by hematopoietic stem cell transplantation""""28 Cyclophosphamide treatment of multiple sclerosis""; ""27 Treatment of multiple sclerosis with methylprednisolone""; ""26 Therapeutic plasma exchange for multiple sclerosis""; ""25 Intravenous immunoglobulin to treat multiple sclerosis""; ""24 Use of mitoxantrone to treat multiple sclerosis""; ""23 Glatiramer acetate as therapy for multiple sclerosis""; ""22 Biological responses to type I interferons: relationship to therapeutic effects in multiple sclerosis"" |
| Notes |
Previous edition: 1999 |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Multiple sclerosis.
|
|
Multiple sclerosis -- Treatment
|
|
Magnetic resonance imaging.
|
|
Outcome assessment (Medical care)
|
|
Multiple Sclerosis -- therapy
|
|
Clinical Trials -- methods
|
|
Magnetic Resonance Imaging
|
|
Multiple Sclerosis -- pathology
|
|
Outcome Assessment, Health Care
|
|
Multiple Sclerosis
|
|
HEALTH & FITNESS -- Diseases -- Alzheimer's & Dementia.
|
|
MEDICAL -- Neurology.
|
|
Outcome assessment (Medical care)
|
|
Magnetic resonance imaging
|
|
Multiple sclerosis
|
|
Multiple sclerosis -- Treatment
|
| Form |
Electronic book
|
| Author |
Cohen, Jeffrey A. (Jeffrey Alan), 1954-
|
|
Rudick, Richard A.
|
| ISBN |
0203639111 |
|
9780203639115 |
|
9781135414023 |
|
1135414025 |
|
9781135414061 |
|
1135414068 |
|
9781135414078 |
|
1135414076 |
|
